skip to main content

H.R. 4278: To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.


The text of the bill below is as of Jun 30, 2021 (Introduced).


I

117th CONGRESS

1st Session

H. R. 4278

IN THE HOUSE OF REPRESENTATIVES

June 30, 2021

(for himself and Mrs. Harshbarger) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.

1.

GAO study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers

(a)

In general

Not later than 180 days after the date of the enactment of this Act, the Comptroller General of the United States shall conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers. Such study shall focus on—

(1)

what steps may be taken by pharmaceutical drug manufacturers and distributors to reduce the higher drug costs paid by consumers as a result of such advertising by splitting the cost of advertising between each organization developing a particular drug;

(2)

the expectations of consumers and patients with respect to the drugs so advertised; and

(3)

the role such advertisements play in promoting medication to patients for whom such medication may not be necessary.

(b)

Report

The Comptroller General shall—

(1)

submit a report containing the results of the study to—

(A)

the Committee on the Judiciary and the Committee on Energy and Commerce of the House of Representatives; and

(B)

the Committee on the Judiciary and the Committee on Health, Education, Labor, and Pensions of the Senate; and

(2)

make such report publicly available.